Breakthrough Technology in Human Plasma Quality Control Webinar

Share Article

Metanomics Health, along with experts and leaders in worldwide biobanking, will present this one-of-a-kind technology which has the potential to revolutionize the industry. On November 12, 2014, they will discuss in a webinar the importance of human plasma quality control in ensuring the robustness of blood samples in scientific research.

A BASF Group Company

From pharmaceutical research and development to CROs and biobanks, the possibilities are endless.

Biopharmaceutical and scientific research can be greatly impacted by the way biological samples such as blood, urine and tissues are collected and processed. In fact, it is a well-known challenge in the biobanking and research fields that unacceptable sample quality can be due to failures in the pre-analytical phase and/or improper sample storage in research studies.

With sample quality being the critical determinant in the success of clinical trials, it is more important than ever to invest in obtaining quality samples for biopharmaceutical research and biobanking. Sample quality is also of paramount importance in the development of biomarkers, companion diagnostics and molecular diagnostics.

In an effort to shed light on the importance of plasma quality control, Metanomics Health has teamed up with One Million Solutions in Health to discuss the challenges and to present a new technology available for quality control during a complimentary webinar on November 12, 2014.

This webinar will feature three industry expert speakers, who are worldwide prominent figures in the industry. They will discuss the overall issues, with a particular focus on the quality control of human EDTA plasma.

Dr. Kurt Zatloukal
Professor in pathology at the Medical University of Graz, Dr. Zatloukal coordinates the preparatory phase of European biobanking and biomolecular research infrastructure for the European Union.

Dr. Fay Betsou
Dr. Betsou is the Chief of Biospecimen Science at the Integrated BioBank of Luxembourg. She will speak on the importance of quality control and the main challenges biobanks face in achieving quality control for fluid biospecimens.

Dr. Philipp Schatz
As head of the Biomarker Program at Metanomics Health GmbH, Dr. Schatz has an in-depth understanding of biomarker discovery and validation, assay development and commercialization. He will speak on a solution to the current problem of obtaining a high level of plasma quality control.

During this webinar, Metanomics Health will introduce a novel metabolomics-based profiling assay, called MxP® Quality Control Plasma. This assay can play an important role in the improvement of human plasma quality control by reducing overall projects costs and, ultimately, playing a significant role in the clinical trials and scientific research being conducted to bring new drugs and other medical breakthroughs to the market.

“The MxP® Quality Control Plasma will be beneficial to all who are involved in research and clinical trials,” says Dr. Schatz. “From pharmaceutical research and development to CROs and biobanks, the possibilities are endless.”

Don’t miss out on this informative and thought-provoking webinar!

New Gold Standard in Quality Control of Biospecimen Studies
Wednesday, November 12, 2014 at 9:00am EST, 3:00pm CET
Register here.

For a more in-depth look at the Metanomics Health MxP® Quality Control Plasma technology, please click here.

About Metanomics Health

Metanomics Health, a BASF Group company, is the world-leading company offering targeted and non-targeted metabolomics to healthcare, nutrition, and bioprocessing partners in industry and academia. In parallel to the service business, Metanomics Health is funding and conducting a comprehensive clinical biomarker program, addressing a wide range of questions with high unmet medical need.

Metanomics Health’s mission is to gain an in-depth understanding of metabolic pathways and their changes in response to disease, pharmaceutical intervention and nutrition, while supporting the development of new therapeutic agents and clinical biomarkers. This will improve overall outcomes for patients through better diagnosis and targeted treatment.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Valentyn Tsygankov
Visit website